For research use only. Not for use in humans.

Epratuzumab (Anti-Siglec-2 / CD22)

Synonyms: Antibody hLL 2 Cat.No.A3056 Purity:99%

Epratuzumab (Anti-Siglec-2 / CD22) is a IgG4 monoclonal antibody targeting CD22. It has been used to research non-Hodgkin’s lymphomas (NHL) and certain autoimmune diseases. MW: 155.4 KD.

Epratuzumab (Anti-Siglec-2 / CD22)

Quality Control

Batch: A305601 Purity: 99% Protein concentration: 15.36mg/ml Endotoxin Level: ＜1EU/mg

99

Specificity

Name	Citation	CD38	CD45	CD39	CD88	CD73	Others
RBN013209	0	++
MK-0159	0	+++
CD38 inhibitor 1 (compound 78c)	7	+++
AB680	0					++++
NQ301	1		+				TXA2 receptor
SodiuM Metatungstate	3			++
PMX-53	3				✔
LY-3475070	2					✔

Expand to Check More

1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description	Epratuzumab (Anti-Siglec-2 / CD22) is a IgG4 monoclonal antibody targeting CD22. It has been used to research non-Hodgkin’s lymphomas (NHL) and certain autoimmune diseases. MW: 155.4 KD.
References	https://pubmed.ncbi.nlm.nih.gov/14506197/

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID

Product Details

CAS No.	205923-57-5
Isotype	Human IgG4SP
Source	CHO
Formulation	100 mM Pro-Ac, 20mM Arg, pH5.0
Storage (From the date of receipt)	Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

^*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.